IPO

Gaudium IVF & Women Health Limited IPO

Mainboard

Healthcare Service Provider

Listed On: Feb 27, 2026 at ₹ 83.0(NSE)

₹ 14931 /189 Shares

Check Allotment

20 Feb, 2026

Open Date

24 Feb, 2026

Close Date

25 Feb, 2026

Allotment Date

27 Feb, 2026

Listing Date
Price Summary

Last Closing

72.50 (-8.23%)

52 Week High

99.75

52 Week Low

69.18

Last Update

30-Mar-2026 3:30 PM
Expected Premium
₹ 0-1 (0%)

*Expected Premium provided in this app is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.

Gaudium IVF & Women Health IPO Live Subscription Details
View Subscription Details
QIB 1.62x
Retail 7.60x
NIIs 14.05x
BHNI 12.71x
SHNI 16.73x
Retail 7.60x
Total 7.27x
Last updated: 24 Feb 2026, 05:57 PM
Gaudium IVF & Women Health IPO Issue Details
  • Issue Price ₹75-79 per equity share
  • Face Value ₹5 Per Equity Share
  • Total Issue Size 2,08,86,200 shares(aggregating up to ₹165 crore)
  • Fresh Share 1,13,92,500 shares(aggregating up to ₹90 crore)
  • Offer For Sale 94,93,700 shares(aggregating up to ₹75 crore)
  • Listing at BSE, NSE
  • List Price 83.0(NSE)
  • Listing Date 2026-02-27
  • Lead Manager Sarthi Capital Advisors Pvt.Ltd.
  • Registrar Bigshare Services Pvt.Ltd.
Market Lot Size

Investors can bid for a minimum of 189 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

Application Lots Shares Amount
Retail (min) 1 189 ₹14,931
Retail(max) 13 2,457 ₹1,94,103
SHNI(min) 14 2,646 ₹2,09,034
SHNI(max) 66 12,474 ₹9,85,446
BHNI(min) 67 12,663 ₹10,00,377
Gaudium IVF & Women Health IPO Reservation

Gaudium IVF & Women Health IPO offers total 20886200 shares. Out of which 4177240 (20%) allocated to QIB, 3132930 (15%) allocated to NII,7310170 (35%) allocated to RII, NA (NA%) allocated to employees and 6265860 (30%) allocated to Anchor investors.

Investor Category Shares Offered Maximum Allottees
Anchor Investor Shares Offered 6265860 (30%)
QIB Shares Offered 4177240 (20%)
NII (HNI) Shares Offered 3132930 (15%)
bNII > ₹10L 2088620 (10%)
sNII < ₹10L 1044310 (5%)
Retail Shares Offered 7310170 (35%)
Total Shares Offered 20886200 (100%)
Gaudium IVF & Women Health IPO Documents
DRHP
RHP
ANCHOR
Gaudium IVF & Women Health IPO Details


Gaudium IVF & Women Health IPO is a book-built issue of ₹165 crores, The total issue size is ₹165 crores. The IPO of Gaudium IVF & Women Health is priced at ₹75-79 per equity share, which has a face value of ₹5 Per Equity Share each, IPO bidding starts from Feb 20, 2026 and ends on Feb 24, 2026. The allotment for Gaudium IVF & Women Health IPO will be finalized on Feb 25, 2026. Gaudium IVF & Women Health IPO will be listed on BSE, NSE, with a tentative listing date fixed as Feb 27, 2026. The company shall list its equity shares on the BSE, NSE. Bigshare Services Pvt.Ltd. is the registrar of the issue.

Retail investors can bid for a minimum of 189 shares, extendable to 14,931. S-HNIs will be able to bid for 2,646 shares at ₹2,09,034, while B-HNIs can also apply for a bid of 12,663 shares at ₹10,00,377. The book-running lead manager for the IPO is/are Sarthi Capital Advisors Pvt.Ltd..

The total issue ₹165 crore, comprising a fresh issue of 1,13,92,500 shares ₹90 crore and having Offer for Sale (OFS) of 94,93,700 shares to mop up ₹75 crore.

The Gaudium IVF & Women Health IPO sets its price band at 75-79 for each share. A single application for Gaudium IVF & Women Health Limited IPO must contain at least 189 shares. Sentiment investors need to invest a minimum of 189 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,931 In order to participate in the sNII, investors must purchase at least 14 lots of 2,646 shares for ₹2,09,034, while the bNII requires 67 lots of 12,663 shares for an investment of ₹10,00,377.

Read More
Gaudium IVF & Women Health IPO Subscription Analysis And Details
Retail
7.60x
QIB
1.62x
NII
14.05x
bNII
12.71x
sNII
16.73x
Total
7.27x
As on QIB NII
bNII   sNII 		Retail Total
Shares Offered / Reserved 41,77,240 31,32,930
20,88,620    10,44,310 		73,10,170 1,46,20,340
Day 1 20-02-26 05:00 PM
0.00 x 0.91 x
0.54 x   1.64 x 		1.39 x 0.89 x
Day 2 23-02-26 05:00 PM
0.02 x 4.62 x
3.52 x   6.83 x 		4.02 x 3.01 x
Day 3 24-02-26 05:00 PM
1.62 x 14.05 x
12.71 x   16.73 x 		7.60 x 7.27 x
Total No of Applications
2,49,030
Subscription on the basis of Applications
Retail:6.22x BHNI:2.51x SHNI:15.94x
Gaudium IVF & Women Health Valuations
EPS Pre IPO ₹3.12/-
EPS Post IPO ₹3.44/-
P/E Pre IPO 25.36
P/E Post IPO 22.99
ROE 41.31%
ROCE 39.70%
Debt/Equity 0.41
RoNW 41.71%
PAT Margin 26.96%
Price to Book Value 10.48
Market Cap. 575.02 Cr.
Gaudium IVF & Women Health Company Financials
In Crs.
In Cr.
30-Sep-25 31-Mar-25 31-Mar-24 31-Mar-23
Assets 106.62 88.51 51.01 36.63
Revenue 49.75 70.96 48.15 44.26
Profit After Tax 12.51 19.13 10.32 13.53
Net Worth 58.85 46.30 26.99 22.73
Reserves & Surplus 28.16 15.60 26.00 21.74
Total Borrowing 22.51 18.93 15.73 9.78
About Gaudium IVF & Women Health Company

Incorporated in March 2015, Gaudium IVF and Women Health Limited have engaged in In Vitro Fertilization treatments throughout India and have expanded into several states utilizing a hub-and-spoke model.

The company has more than thirty locations. These include seven hubs (centres) and twenty-eight spokes. The strategic alliance between the organization and Infertility Experts, referred to as Spokes, was forged in order to meet the mutual goal of spreading awareness about Assisted Reproductive Technology or ART and In Vitro Fertilization or IVF treatments.The patients come from various countries such as Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman.
The company has hubs in Delhi, two Janakpuri and Kailash Colony; Mumbai; Khar West; Ludhiana; Srinagar; Patna; and Bangalore, covering all important locations across the subcontinent.
This company offers a range of specialized fertility services: In Vitro Fertilization, Intracytoplasmic Sperm Injection, Intrauterine Insemination, and ovulation induction. Our treatments are specifically directed for a variety of infertility conditions in both males and females. We also provide comprehensive gynaecological care for PCOD/PCOS and endometriosis and high-risk pregnancy management for women with complex fertility history or health conditions.
These facilities cover a wide scope of male infertility treatments, right from advanced sperm retrieval techniques.

Read More
Gaudium IVF & Women Health - Promoter(s)

Dr. Manika Khanna

Dr. Peeyush Khanna

Vishad Khanna

Pre Issue Share Holding : 99.99%

Post Issue Share Holding : 71.30%

Gaudium IVF & Women Health IPO - Issue Objectives
1

Funding capital expenditure towards establishment of New IVF Centers of the Company - ₹50 Cr.

2

Repayment/pre-payment, in full or in part, of certain outstanding loans availed by our Company - ₹20 Cr.

3

General Corporate Purpose

Gaudium IVF & Women Health IPO - Anchor Investors

Gaudium IVF mobilises Rs 49.5 crore through anchor book for Rs 165-crore IPO.
Gaudium IVF has allocated 62.65 lakh shares to four anchor investors at the higher price band. Meru Investment Fund was the largest among the anchor investors, investing close to Rs 17 crore for 21.51 lakh shares, followed by Sanshi Fund, which invested 15.8 lakh shares worth Rs 12.5 crore.
Hornbill Orchid India Fund, and Carnelian India Multi-Strategy Fund invested 12.6 lakh shares worth Rs 10 crore each.

Gaudium IVF & Women Health IPO - Peers Comparison
P/B Ratio P/E Ratio RoNW Revenue(in Cr.)
Gaudium IVF N/A N/A 41.71% 70
Progyny Inc. 5.22 41.56 12.90% 10128
Inspire IVF 0.25 11.43 3.97% 26
Strength
Patient Centric Pricing Approach: The Company offers package-based treatments, bundled services, and installment facilities to make fertility treatments more affordable for the middle-income group. This increases patient trust as well as the customer base.
Strong Brand Positioning & Trust Creation: The Company undertakes intensive patient education, brand credibility, and stigma reduction through patient education. It also obtains accreditations from recognized medical associations to enhance brand credibility and trust.
Focus on Medical Tourism: The Company takes advantage of the cost advantage of doing business in India. It attracts international patients through multiple language support, concierge services, and tie-ups with international agencies. It has tie-ups with international agencies to ensure a steady flow of international patients.
Weakness
Operational & Medical Risks in Fertility Services: The Company provides fertility services like IVF, IUI, ICSI, and egg freezing, which expose the company to medical and operational risks. If the company fails to meet medical and healthcare standards, it may affect its reputation and financial performance.
Related Party Transactions & Potential Conflicts: The Company may have entered into and may continue to enter into related party transactions, which may include loans, advances, and guarantees to related parties.
Dependence on Limited Embryologists: The company operates across seven locations and relies on the services of five embryologists. The inability to retain and recruit qualified embryologists may affect the company's operations and financial condition.
Contact Details

Gaudium IVF & Women Health

B1/51, Janak Puri, B-1, New Delhi, New Delhi, 110058

011-4885 8585

compliance@gaudiumivfcentre.com

https://www.gaudiumivfcentre.com/

Registrar Contact Details

Bigshare Services Pvt Ltd

+91-22-6263 8200

ipo@bigshareonline.com

https://ipo.bigshareonline.com/ipo_status.html